APH - Alliance Pharma plc
LSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Chippenham,
United Kingdom
Type: Equity
APH price evolution
APH
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $2571.2 | $2443.5 | $2411.9 | $2631.3 |
| Inventory | $2099.1 | $1997.8 | $2105.1 | $2093.6 |
| Total current assets | $6773.3 | $6321.3 | $6394 | $6479.1 |
| Long term investments | ||||
| Property, plant & equipment | $1246.6 | $1258.9 | $1243.5 | $1204.3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $15759 | $15237.9 | $15381.5 | $15326.2 |
| Current liabilities | ||||
| Accounts payable | $1248.9 | $1116.8 | $1182.1 | $1309.1 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2908.8 | $2709.7 | $2426.2 | $2676.1 |
| Long term debt | $3936.4 | $3967.4 | $4561 | $4575 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $7902.2 | $7724.2 | $8073.4 | $8310.6 |
| Shareholders' equity | ||||
| Retained earnings | $5669.7 | $5294.8 | $5121.3 | $4979.4 |
| Other shareholder equity | -$657.9 | -$592.5 | -$492.6 | -$535 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.06 | $28.9 | $17.83 | |
| Short term investments | ||||
| Net receivables | $2631.3 | $27.72 | $24.22 | $30.29 |
| Inventory | $2093.6 | $21.07 | $22.92 | $15.52 |
| Total current assets | $6479.1 | $81.02 | $77.24 | $65.04 |
| Long term investments | ||||
| Property, plant & equipment | $1204.3 | $4.46 | $4.49 | $4.21 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $15326.2 | $503.49 | $508.85 | $407.64 |
| Current liabilities | ||||
| Accounts payable | $1309.1 | $8.34 | $11.28 | $6.97 |
| Deferred revenue | ||||
| Short long term debt | $0.05 | |||
| Total current liabilities | $2676.1 | $40.58 | $30.19 | $24.21 |
| Long term debt | $4575 | $116.06 | $138.33 | $77.04 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $8310.6 | $221 | $227.9 | $133.46 |
| Shareholders' equity | ||||
| Retained earnings | $4979.4 | $116.42 | $117.7 | $112.51 |
| Other shareholder equity | -$535 | $9.36 | $7.28 | $7.34 |
| Total shareholder equity | $282.49 | $280.96 | $274.18 | |
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3199.2 | $3053.9 | $2974 | $3239.2 |
| Cost of revenue | ||||
| Gross Profit | $1048.5 | $991.7 | $943.4 | $1037.5 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $381.6 | $367.8 | $346.3 | $361.9 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $115.2 | $130.6 | $117.2 | $121.4 |
| Interest expense | -$33.6 | -$35 | -$35.9 | -$37.1 |
| Net income | ||||
| Net income | $513.9 | $460.5 | $439.2 | $507.5 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12623 | $163.21 | $129.8 | $135.64 |
| Cost of revenue | $53.76 | $46.98 | $49.56 | |
| Gross Profit | $4028.2 | $109.45 | $82.82 | $86.08 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $60.63 | $44.61 | $46.35 | |
| Total operating expenses | $1420.9 | $125.16 | $100.13 | $97.91 |
| Operating income | $38.05 | $29.67 | $37.73 | |
| Income from continuing operations | ||||
| EBIT | $38.05 | $29.67 | $37.73 | |
| Income tax expense | $550.6 | $10.84 | $4.99 | $6.07 |
| Interest expense | -$128.4 | -$3.65 | -$2.66 | -$3.78 |
| Net income | ||||
| Net income | $1902.3 | $7.32 | $8.03 | $25.01 |
| Income (for common shares) | $7.32 | $8.03 | $25.01 | |
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$704.4 | -$375.1 | -$256.6 | -$731.1 |
| Financing activities | ||||
| Dividends paid | -$375 | -$249.9 | -$124.9 | -$477.4 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$822.4 | -$704 | -$265.4 | -$1196.7 |
| Effect of exchange rate | -$51.7 | -$37.7 | $7.6 | -$70.8 |
| Change in cash and equivalents | $108.4 | -$48 | $18 | $176 |
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Net income | $7.32 | $8.03 | $25.01 | |
| Operating activities | ||||
| Depreciation | $8.74 | $8.91 | $1.68 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $38.66 | $41.57 | $35.76 | |
| Investing activities | ||||
| Capital expenditures | -$1.53 | -$4.61 | -$4.14 | |
| Investments | $0.5 | |||
| Total cash flows from investing | -$731.1 | -$4.6 | -$85.86 | -$3.28 |
| Financing activities | ||||
| Dividends paid | -$477.4 | -$8.6 | -$2.84 | -$7.6 |
| Sale and purchase of stock | ||||
| Net borrowings | -$23.51 | $60.17 | -$18.2 | |
| Total cash flows from financing | -$1196.7 | -$34.34 | $55.75 | -$25.2 |
| Effect of exchange rate | -$70.8 | $0.45 | -$0.38 | -$0.34 |
| Change in cash and equivalents | $176 | $0.16 | $11.07 | $6.94 |
News
Fundamentals
| Market cap | $23.08B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 596.45M |
| Revenue | $12.47B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $1.92B |
| Revenue Q/Q | -2.91% |
| Revenue Y/Y | 264.91% |
| P/E ratio | 12.02 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.85 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $3.22 |
|---|---|
| ROA | 12.45% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.33 |
| Quick ratio | 1.61 |